A Study Evaluating the Safety Tolerability and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Updated on 27 January 2021


This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies

Condition Advanced Malignancies
Treatment IBI939, IBI939+ Sintilimab
Clinical Study IdentifierNCT04353830
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

Able to understand and willing to sign the ICF
Adults 18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy at least 12 weeks
Adequate organ and bone marrow function
Eligibility Criteria
Previous exposure to any anti-TIGIT antibody
Participate in another interventional clinical study, except for the observational (non-interventional) clinical study or the survival follow-up phase of the interventional study
Any investigational drugs received within 4 weeks prior to the first study treatment
Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy
Immunosuppressive drugs were used within 4 weeks prior to the first administration of the study drug
Medication requiring long-term systemic hormones or any other immunosuppression therapy
Major surgical procedures (craniotomy, thoracotomy, or laparotomy) or unhealed wounds, ulcers, or fractures were performed within 4 weeks prior to the first dose of study therapy
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases, or leptomeningeal disease
History of autoimmune disease , present active autoimmune disease or inflammatory diseases
Positive human immunodeficiency virus (HIV) test
Active hepatitis B or C, or tuberculosis
History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Known history of hypersensitivity to any components of the IBI939 or Sintilimab
Pregnant or nursing females
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note